NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
that it has been issued U.S. patent number 10815271 (application
number 16/311,593) from the United States Patent and Trademark
Office (USPTO) covering the composition of matter for SLS-007, a
potentially disease-modifying gene therapy focused on intracellular
alpha-synuclein (α-synuclein) aggregates in Parkinson's disease
(PD).
This patent covers the composition of matter comprising at least
one inhibitory peptide that inhibits α-synuclein aggregation by
binding to residues 68-78 of α-synuclein. The patent also covers a
method of use for reducing or inhibiting α-synuclein aggregation,
comprising contacting α-synuclein amyloid fibrils with an
inhibitory peptide in an amount sufficient to reduce or inhibit
α-synuclein aggregation plus a method of modulating the size or
rate of growth of α-synuclein amyloid fibrils.
As previously announced, Seelos is currently conducting an in
vivo preclinical study of SLS-007.
"The alpha-synuclein approach to treating Parkinson's disease
has been of great interest recently and we look forward to
completing this study and evaluating the results," said Raj Mehra,
Ph.D., Chairman and CEO of Seelos. "Successful delivery of this
peptide by a gene therapy approach could yield a valuable tool in
slowing the progression of Parkinson's by stopping the seeding and
potential propagation of alpha-synuclein aggregates."
Seelos is currently delivering SLS-007 via an adeno-associated
virus (AAV) that is designed to target the non-amyloid component
core (NACore) of α-synuclein to inhibit protein aggregation in
patients with Parkinson's Disease (PD). The preclinical study is
designed to establish the in vivo pharmacokinetic and
pharmacodynamic profiles and target engagement parameters of
SLS-007.
Preliminary data from the study is currently expected in Q1
2021.
About SLS-007
SLS-007 is a family of rationally designed peptidic inhibitors
that target the NACore of α-synuclein to inhibit protein
aggregation in patients with PD. The overexpression of α-synuclein
leads to the formation of α-synuclein aggregates which comprise
Lewy bodies and neurites which are the hallmarks of the
pathogenesis of PD. Recent in vitro and cell culture research have
shown that SLS-007 has the potential to stop the propagation and
seeding of α-synuclein aggregates.
Forward Looking Statements
Statements made in this press release, which are not
historical in nature, constitute forward-looking statements for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, among
others, those regarding the potential for SLS-007 to be a
disease-modifying gene focused on intracellular α-synuclein
aggregates in PD, the initiation and completion of the preclinical
study of SLS-007, the ability of SLS-007 and related peptides to
slow the progression of PD by stopping the seeding and potential
propagation of α-synuclein aggregates, the ability of SLS-007
delivered via an AAV to target the NACore, expectations regarding
the results of the study, including the establishment of the in
vivo pharmacokinetic and pharmacodynamics profiles and target
engagement parameters of SLS-007 and the expected timing for
releasing preliminary data regarding the study. These statements
are based on Seelos' current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Risks associated with Seelos' business
include, but are not limited to, the risk of not successfully
executing its preclinical and clinical studies and not gaining
marketing approvals for its product candidates, the risk that prior
test results may not be replicated in future studies and trials,
the risks that clinical study results may not meet any or all
endpoints of a clinical study and that any data generated from such
studies may not support a regulatory submission or approval, the
risks associated with the implementation of a new business
strategy, the risks related to raising capital to fund its
development plans and ongoing operations, risks related to Seelos'
current stock price, risks related to the global impact of
COVID-19, as well as other factors expressed in Seelos' periodic
filings with the U.S. Securities and Exchange Commission, including
its Annual Report on Form 10-K and Quarterly Reports on Form
10-Q. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, even if subsequently made
available by us on our website or otherwise. We do not undertake
any obligation to update, amend or clarify these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
laws.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-issuance-of-composition-of-matter-patent-for-sls-007-301158878.html
SOURCE Seelos Therapeutics, Inc.